Aethlon Medical Advances Oncology Trials and Global Expansion
Company Announcements

Aethlon Medical Advances Oncology Trials and Global Expansion

Aethlon Medical ( (AEMD) ) just unveiled an update.

Aethlon Medical, Inc. has reported significant advancements in its oncology trials, enrolling the first two patients in its Hemopurifier® study for those with solid tumors not responding to anti-PD-1 antibodies. The company has also opened two sites in Australia for patient enrollment and received ethics approval for a trial in India. Aethlon is focusing on strategic cost-cutting measures and optimizing resources to support high-impact trials, aiming to enhance therapeutic responses and expand its Hemopurifier’s use against viral infections.

For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAethlon Medical reports Q3 EPS (20c) vs. ($1.22) last year
TheFlyAethlon Medical enrolls first patient in Hemopurifier cancer trial in Australia
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App